Choose Your Country or Region

Anti-HLTF Rabbit Antibody [N4E14]

Catalog No.: F3714

Application: Reactivity: Human

Usage Information

Dilution
WB1:10000 - 1:50000 IHC1:50 - 1:100 IF1:100

Application
WB, IHC, IF

Reactivity
Human

Source
Rabbit

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
114 kDa 113 kDa
^*Why do the predicted and actual molecular weights differ? The following reasons may explain differences between the predicted and actual protein molecular weight.

Datasheet & SDS

Biological Description

Specificity
Anti-HLTF Rabbit Antibody [N4E14] detects endogenous levels of total HLTF protein.

Clone
N4E14

Synonym(s)
HIP116A, RNF80, SMARCA3, SNF2L3, ZBU1, HLTF, Helicase-like transcription factor, DNA-binding protein/plasminogen activator inhibitor 1 regulator, HIP116, RING finger protein 80

Background
HLTF (Helicase-like Transcription Factor) is a member of the SWI/SNF family of chromatin remodeling proteins that functions as a tumor suppressor by maintaining genome stability. The human HLTF gene, located on chromosome 3q25.1-q26.1, encodes a 1,009–amino acid protein comprising three main domains: the N-terminal HIRAN domain, which binds the 3′-end of DNA at stalled replication forks; a SWI/SNF helicase domain divided into N- and C-terminal regions facilitating DNA translocation and fork regression; and a RING E3 ubiquitin ligase domain, which mediates polyubiquitination of PCNA to promote template switching during DNA damage tolerance. HLTF is widely expressed in human tissues, with highest levels in brain, heart, and testes, and undergoes alternative splicing that can generate truncated proteins lacking DNA repair domains. Functionally, HLTF regulates transcription, DNA repair, sister chromatid cohesion, chromosome condensation, and replication fork regression, thereby preserving genomic stability. Alterations in HLTF expression, through promoter hypermethylation or aberrant splicing, are observed in various cancers and are associated with poor prognosis, indicating that HLTF loss acts as a driver in tumor progression.

Background

HLTF (Helicase-like Transcription Factor) is a member of the SWI/SNF family of chromatin remodeling proteins that functions as a tumor suppressor by maintaining genome stability. The human HLTF gene, located on chromosome 3q25.1-q26.1, encodes a 1,009–amino acid protein comprising three main domains: the N-terminal HIRAN domain, which binds the 3′-end of DNA at stalled replication forks; a SWI/SNF helicase domain divided into N- and C-terminal regions facilitating DNA translocation and fork regression; and a RING E3 ubiquitin ligase domain, which mediates polyubiquitination of PCNA to promote template switching during DNA damage tolerance. HLTF is widely expressed in human tissues, with highest levels in brain, heart, and testes, and undergoes alternative splicing that can generate truncated proteins lacking DNA repair domains. Functionally, HLTF regulates transcription, DNA repair, sister chromatid cohesion, chromosome condensation, and replication fork regression, thereby preserving genomic stability. Alterations in HLTF expression, through promoter hypermethylation or aberrant splicing, are observed in various cancers and are associated with poor prognosis, indicating that HLTF loss acts as a driver in tumor progression.

References
https://pubmed.ncbi.nlm.nih.gov/25858588/ https://pubmed.ncbi.nlm.nih.gov/26472339/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%